Skip to main content

Table 3 Effectiveness of three consecutive monthly doses of Credelio Plus® and afoxolaner + milbemycin oxime based on laboratory counts and speciation of natural flea infestations for dog, cat and human flea species on client owned dogs in European field study

From: Field study to investigate the effectiveness and safety of a novel orally administered combination drug product containing milbemycin oxime and lotilaner (Credelio® Plus) against natural flea and tick infestations on dogs presented as veterinary patients in Europe

Study day

Treatment group

C. felis

C. canis

P. irritans

AM flea count

% Effectiveness

AM flea count

% Effectiveness

AM flea count

% Effectiveness

0

Credelio Plus®

18.5

11.4

6.6

 

Afoxolaner + Milbemycin oxime

10.4

20.7

10.5

14 ± 2

Credelio Plus®

0.25

98.6

0

100

0

100

 

Afoxolaner + Milbemycin oxime

0.09

99.1

0.09

99.6

0.06

99.4

28 ± 2

Credelio Plus®

0.07

99.6

0

100

0

100

 

Afoxolaner + Milbemycin oxime

0.63

94.0

0

100

0

100

56 ± 2

Credelio Plus®

0

100

0

100

0

100

 

Afoxolaner + Milbemycin oxime

0.10

99.0

0

100

0

100

84 ± 2

Credelio Plus®

0

100

0

100

0–0

100

 

Afoxolaner + Milbemycin oxime

0

100

0

100

0–0

100

  1. Before treatment administration on Day 0, the number of dogs in the Credelio Plus® and afoxolaner + milbemycin oxime groups infested with each species was 58 and 32 for C. felis, 29 and 11 for C. canis and 18 and 10 for P. irritans, respectively